| World Journal of Nephrology and Urology, ISSN 1927-1239 print, 1927-1247 online, Open Access |
| Article copyright, the authors; Journal compilation copyright, World J Nephrol Urol and Elmer Press Inc |
| Journal website https://wjnu.elmerpub.com |
Case Report
Volume 000, Number 000, August 2026, pages 000-000
Organ-Preserving Chemoradiotherapy and Successful Metastasectomy in a Rare Epithelioid Leiomyosarcoma of the Prostate
Figures



Tables
| Time point | Event |
|---|---|
| DRE: digital rectal examination; USG: ultrasonography; CT KUB: computed tomography of the kidneys, ureters, and bladder; MRI: magnetic resonance imaging; PET-CT: positron emission tomography–computed tomography; VMAT: volumetric modulated arc therapy; VATS: video-assisted thoracoscopic surgery. | |
| Initial presentation | Burning micturition, haematuria, pelvic pain; DRE: cystic–firm mass at 4 cm from anal verge; normal labs. |
| Baseline imaging | USG, CT KUB, MRI pelvis: heterogeneous mass at left prostate–seminal vesicle junction with rectal and bladder indentation. |
| Staging | PET-CT: peripherally enhancing necrotic lesion in prostate, interpreted as likely inflammatory mass; no distant disease. |
| Diagnostic procedure | Cystoscopy and transrectal biopsy with aspiration of cystic component; IHC confirming high-grade epithelioid leiomyosarcoma. |
| Primary treatment | Neoadjuvant ifosfamide–doxorubicin chemotherapy followed by VMAT-based external beam radiotherapy; complete metabolic response on PET-CT. |
| Metachronous event | Approximately one year later: acute intestinal obstruction; jejunal resection confirming grade 2 leiomyosarcoma; PET-CT revealed right lung nodule. |
| Management of metastases | Gemcitabine–docetaxel chemotherapy followed by VATS right lung lobectomy; patient well on follow-up. |
| Marker | Result |
|---|---|
| 34βE12: high molecular weight cytokeratin; CD: cluster of differentiation; CK: cytokeratin; EMA: epithelial membrane antigen; ERG: ETS-related gene; H-caldesmon: heavy caldesmon; HMB45: human melanoma black 45; Ki-67: Kiel 67 proliferation index; melan-A: melanoma antigen A; P63: tumor protein p63; S-100: S100 protein; SMA: smooth muscle actin. | |
| CK | Locally positive |
| Vimentin | Strongly and diffusely positive |
| Calponin | Positive |
| SMA | Positive |
| Desmin | Positive |
| H-Caldesmon | Positive (initial workup) |
| CK5/6, P63, EMA, 34βE12 | Negative |
| Vascular markers (CD31, CD34, D2-40, ERG) | Negative |
| Melanocytic markers (HMB45 and Melan-A) | Negative |
| S-100 | Negative |
| Ki-67 proliferation index | 30–40% in the primary prostate lesion |